Biocytogen Pharmaceuticals Beijing Co Ltd has formed a groundbreaking partnership with Merck KGaA to develop innovative antibody-conjugated lipid-based delivery solutions for targeted nucleic acid therapies, potentially revolutionizing the biopharma…

Biocytogen Pharmaceuticals has achieved key milestones in patent acquisition and drug development, including a patent in Japan and IND approval for its anti-IGF-1R antibody NTB003.

Biocytogen Pharmaceuticals has secured a key patent and received IND approval for its anti-IGF-1R antibody, NTB003, which is being developed for the treatment of Thyroid Eye Disease.

Biocytogen Pharmaceuticals Beijing Co Ltd faces high stakes in the biopharmaceutical industry, with its financial performance and market valuation raising questions about its sustainability and future growth.